Amatuximab
Amatuximab
Amatuximab (pronunciation: a-ma-tux-i-mab) is a monoclonal antibody designed for the treatment of mesothelioma. It is also known as MORAb-009.
Etymology
The name "Amatuximab" is derived from the Latin word "Amatus" meaning "loved" and the Greek word "ximab" meaning "antibody". The name signifies the hope that this antibody will be a much-loved treatment for mesothelioma.
Function
Amatuximab works by binding to the mesothelin protein, which is overexpressed in several types of cancer, including mesothelioma. By binding to mesothelin, Amatuximab inhibits the growth and spread of cancer cells.
Clinical Trials
Amatuximab has been tested in several clinical trials. In a phase II clinical trial, it was combined with Pemetrexed and Cisplatin for the treatment of patients with unresectable malignant pleural mesothelioma.
Related Terms
External links
- Medical encyclopedia article on Amatuximab
- Wikipedia's article - Amatuximab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski